PRONOVA SLM20

$100,00 / vial of 250 mg

Minimum order is one vial of 250mg

Clear
SKU: Product# 4202221 Category:

Description

PRONOVA™ SLM20 is made from an alginate where over 50% of the monomer units are mannuronate and is a highly purified and well-characterized sodium alginate. One of the functional properties of alginate is viscosity. The viscosity of an alginate solution can be manipulated by changing the concentration of the alginate or by using materials with varying chain length (i.e. molecular weight). Typically, the molecular weight for PRONOVA™ SLM20 is in the 75000 – 220000 g/mol range. The ultra low levels of endotoxins, proteins and product sterility allows for a big variety of in vitro and in vivo applications.

  • Viscosity  [mPa*s] :  20-99
  • Appr. Mw [kDa] : 75-150
  • G/M Ratio : ≤ 1
  • Endotoxins [EU/g] : ≤ 100
  • Total viable count [cfu/g] : Sterile

Specifications

Generic Name

Sodium alginate

Dry matter content

100% freeze-dried material

Storage conditions

2-8°C

Shelf life

5 years

Packaging material

Glass vial

ID-test

Positive

Appearance of powder

White to off-white

Appearance of solution

Clear, colorless to slightly yellowish

Apparent viscosity

20 – 99 mPa/s

pH

5.5-8.5

Mannuronic acid content

≥ 50%

Protein content

≤ 0.3%

Endotoxins

≤ 100 EU/gram

Heavy metals

≤ 40 ppm

Pb

≤ 10 ppm

Hg

≤ 1 ppm

Microbiological purity

Sterile

Quality

NovaMatrix® produces and supplies well-characterized and documented ultrapure, bio-compatible and bio-absorbable biopolymers for use in the pharmaceutical, biotechnology and biomedical industries.

These may include, but not be limited to applications such as drug delivery, tissue engineering, cell encapsulation, and medical devices. For our ultrapure sodium alginates and sodium hyaluronate, we maintain Drug Master Files with the US FDA.

NovaMatrix® products are intended to be used in applications which require high and consistent quality provided by our manufacturing, Quality Control and Quality Assurance. NovaMatrix® manufacture PRONOVA™ sodium alginate in our facilities in Norway. We operate according to GMP guidelines; ICH Q7, ICH Q1, ICH Q2 and ISO standards; ISO 9001:2008 and ISO 13485:2003.

Furthermore NovaMatrix® holds the Manufacturing License for API’s issued by the Norwegian Medicine Agency (NOMA). Our Sodium Hyaluronate ultrapure products are produced using non-animal origin sources by our partner, Kikkoman Biochemifa Company, Japan, under GMP guidelines; the Pharmaceutical and Madical Devices Act, ICH Q7 and ISO standards; ISO 9001:2008 and ISO 14001:2004.

Safety & toxicology

PRONOVA™ UP sodium alginates are manufactured in accordance with GMP, ISO and ICH guidelines. Ultrapure (UP) implies that the products contain low levels of residual endotoxin. The current specification is <100 EU/g. PRONOVA™ sodium alginate products are ideal for a wide variety of pharmaceutical, biomedical, biotechnology and tissue engineering applications. The safety and toxicology profile of ultrapure PRONOVA™ sodium alginate products is described in a Drug Master File submitted to the US FDA. The table below is meant to serve as a summary over some of the studies performed and the conclusions drawn from them.

Report number : ALG-95-001

  • Animal species : In vitro cell culture 3T3 mouse fibroblasts V79 Chinese hamster
  • Alginate products : PRONOVA™ UP LVG (132 mPas) – PRONOVA™ UP MVG (230 mPas)
  • Concentration : 0-1 mg/ml
  • Conclusion : Little or no effect on cell survival and colony-forming ability.
Report number : 658/521

  • Animal species : Mouse
  • Alginate products : PRONOVA™ UP MVG (230 mPas)
  • Concentration : 100, 250, 500 mg/kg
  • Conclusion : No mortality. No abnormal clinical signs, normal weight increase.
Report number : 658/522

  • Animal species : Rat
  • Alginate products : PRONOVA™ UP MVG (230 mPas)
  • Concentration : 100, 250, 500 mg/kg
  • Conclusion : No mortality. No abnormal clinical signs, normal weight increase.
Report number : 658/523

  • Animal species : Mouse
  • Alginate products : PRONOVA™ UP LVG (132 mPas)
  • Concentration : 100, 250, 500 mg/kg
  • Conclusion : No mortality. No abnormal clinical signs, normal weight increase.
Report number : 658/524

  • Animal species : Rat
  • Alginate products : PRONOVA™ UP LVG (132 mPas)
  • Concentration : 100, 250, 500 mg/kg
  • Conclusion : No mortality. No abnormal clinical signs, normal weight increase.
Report number : 658/529

  • Animal species : Rat
  • Alginate products : PRONOVA™ UP LVG (30 mPas)
  • Concentration : 100, 250, 500 mg/kg
  • Conclusion : No mortality. No abnormal clinical signs, normal weight increase.
Report number : 658/530

  • Animal species : Rat
  • Alginate products : PRONOVA™ UP LVG (3.5 mPas)
  • Concentration : 100, 250, 500 mg/kg
  • Conclusion : No mortality. No abnormal clinical signs, normal weight increase.
Report number : 658/534

  • Animal species : Rat
  • Alginate products : Poly mannuronic acid – high molecular weight, intrinsic viscosity 16 dl/g
  • Concentration : 1, 10, 100 mg/kg
  • Conclusion : No mortality in 1 and 10 mg/kg groups, 50% mortality in 100 mg/kg group. No abnormal clinical signs in 1 of 10 mg/kg groups.
Report number : 658/535

  • Animal species : Rat
  • Alginate products : Poly mannuronic acid – low molecular weight, intrinsic viscosity 6.8 dl/g
  • Concentration : 1, 10, 100 mg/kg
  • Conclusion : No mortality. No abnormal clinical signs, normal weight increase.
Report number : Poly-M-94-1

  • Animal species : Mouse
  • Alginate products : Poly mannuronic acid (14C-labelled)
  • Concentration : 5 mg/kg
  • Conclusion : Oral: No absorption, IV: half-life approx. 4 hr, IP: half-life approx. 12.5 hr, Elimination via urine.

Application examples

anti-adhesion,additives for cryopreservation of cells/tissues, sealants, drug delivery, 3D printing, 3D cell culture, hydrogels, extracellular matrix scaffolds, internal wound healing.